1. Home
  2. GROY vs CMPX Comparison

GROY vs CMPX Comparison

Compare GROY & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GROY

Gold Royalty Corp.

HOLD

Current Price

$4.94

Market Cap

938.2M

Sector

N/A

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.72

Market Cap

926.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROY
CMPX
Founded
2020
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
938.2M
926.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GROY
CMPX
Price
$4.94
$5.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$5.15
$13.44
AVG Volume (30 Days)
3.0M
2.5M
Earning Date
11-05-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,464,000.00
N/A
Revenue This Year
$72.11
N/A
Revenue Next Year
$100.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
86.30
N/A
52 Week Low
$1.20
$1.33
52 Week High
$5.05
$6.25

Technical Indicators

Market Signals
Indicator
GROY
CMPX
Relative Strength Index (RSI) 75.93 58.06
Support Level $4.16 $5.09
Resistance Level $4.45 $6.25
Average True Range (ATR) 0.19 0.43
MACD 0.07 0.05
Stochastic Oscillator 90.54 64.04

Price Performance

Historical Comparison
GROY
CMPX

About GROY Gold Royalty Corp.

Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: